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Resotution of Type-2 diabetes metlitus (DM) after weight toss surgery is well documented, but the
mechanism is elusive. We evatuated the glucose-insulin metabolism of patients undergoing a
Roux-en-Y gastric bypass (RYGB) using the intravenous glucose tolerance test (tVGTT) and
compared it with patients who underwent laparoscopic adjustable gastric band (AB) placement.
Thirty-one female patients (age range, 20 to 50 years; body mass index, 47.2 kg/m )̂ underwent
RYGB. Nine female patients underwent AB placement and served as control subjects. All patients
underwent IVGTT at baseline and 1 month and 6 months after surgery. Thirteen patients
undergoing RYGB and one patient undergoing AB exhibited impaired glucose tolerance defined
by the American Diabetes Association. By 6 months post surgery, diabetes was resolved in alt but
one patient undergoing RYGB and none of the patients undergoing AB. Patients with diabetes
undergoing demonstrated increased insulin secretion and ß-cell responsiveness 1 month after
surgery and continued this trend up to 6 months, whereas none of the patients undergoing AB had
changes in ß-cell function. Both patients undergoing RYGB and those undergoing AB demon-
strated significant weight loss (34.6 and 35.0 kg/rcr, respectively) and improved insulin sensitivity
at 6 months. RYGB ameliorates DM resolution in two phases: 1) early augmentation of beta cell
function at 1 month; and 2) attenuation of peripheral insulin resistance at 6 months. Patients
undergoing AB only exhibited reduction in peripheral insulin resistance at 6 months but no
changes in insulin secretion.
R ESOLUTION OF TYPE-2 diabetes mellitus (T2DM)after weight loss surgery has been well docu-
mented with gastric hypass operations,'~^ hut there is
evidence that the restrictive adjustable band procedure
also promotes T2DM resolution."* The mechanisms of
diabetes resolution are presumably different between a
malabsorptive operation such as the Roux-en-Y gastric
hypass (RYGB) and the restrictive adjustable gastric
band (AB). The drastically distinct surgical approaches
to weight loss surgery aiming to achieve the same
benchmark of T2DM resolution beg the question of
which operation is most appropriate for a morbidly obese
patient with dysfunction of insulin-glucose metabolism.
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If both procedures are eventually equal in efficacy, the
mere cost and surgical risk reduction of the simpler
procedure would clearly be the best choice, and yet
there are data that the mere diversion of food from the
proximal gastrointestinal tract (eg, biliopancreatic
diversiori, RYGB) offers profound and almost imme-
diate relief (less than 1 month) from T2DM.^~'
In this study, we used a standardized intravenous
glucose tolerance test (IVGTT) to determine the base-
line characteristics and subsequent response of insulin-
glucose metabolism in morbidly obese patients with
T2DM undergoing either RYGB or the AB. We hy-
pothesize that RYGB induces alterations in pancreatic
ß-cell function, which is not observed with the AB
procedure. Knowing this information may help patients
and surgeons determine which procedures are most
appropriate for them based on their baseline phenotype.
Methods
Patients and Inclusion Criteria
Women between the ages of 18 and 50 years were
recruited into the study with ongoing treatment for
T2DM and HgA|C greater than 6 per cent. The choice
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of surgery was a decision between the patients and
their surgeons, but patients generally presented after
having decided on their preferred procedure based on
completely psychosocial rationale (eg, risk fear, ac-
quaintance with the same surgery, permanent foreign
body, complexity of procedure). Exclusion criteria
were male, age younger than 18 or older than 50 years,
body mass index (BMI) less than 35 kg/m^, and current
smoking history.
Surgical Procedures
RYGB were performed laparoscopically in all
patients. In brief, a 20- to 30-mL gastric pouch is
Wmed in a longitudinal fashion. The Roux limb is
typically 100 to 150 cm in length. Patients undergoing
B patients had the Lap-Band system (Allergan Inc.,
Irvine, CA) with the first band fill 4 to 6 weeks after
surgery with the aid of fluoroscopy and contrast
esophagram to rapidly achieve optimal restriction.
Study Protocol
The study has had 6 years of continuous approval by
the Institutional Review Board of Emory University,
and metabolic evaluations were all conducted in the
Atlanta Clinical and Translational Studies Institute
(CTSl, formerly the General Clinical Research Center
of Emory University). Patients admitted to the CTSl
had the following measurements: IVGTT, anthrop-
ometry, and adipose tissue distribution. All measure-
ments were obtained at baseline (0 months) and 1, 6,
and 24 months after surgery. However, for the purposes
of this study, the acute changes of interest were only
within the llrst 6 months after surgery because very
little metabolic change was anticipated at 24 months.
Subjects were weight-stable (±1 kg) for 1 week before
each measurement time point, with the exception of
I month in which significant weight loss occurs
(approximately 3 kg/week). Medications were with-
held on the morning of the glucose tolerance testing.
Intravenous Glucose Tolerance Test, ß-Cell Function,
Insulin Sensitivity
Insulin action was assessed using the frequently
sampled IVGTT. Patients were admitted to the CTSl
the night before testing and fasted overnight (12
hours). Intravenous access was established for blood
sampling, and the study began as previously descri-
bed.** A standard approach using minimal modeling
analysis^^ (MinMod Millennium, Los Angeles, CA) of
glucose and insulin levels was used to quantify insulin
sensitivity (Si, a measure of peripheral resistance),
acute insulin response to glucose (AIRg, a measure of
ß-cell function and insulin secretion), and disposition
index (Dl = Si X AIRg), a quantitative measurement
that describes the dynamic relationship between ß-cell
responsiveness and insulin sensitivity. In metabolically
normal individuals, changes in insulin sensitivity are
accompanied by compensatory alterations in the ß-
cell's sensitivity to glucose. Patients with T2DM typ-
ically have lower DI than normal individuals. Patient
hemoglobin A|C (HgA|C) was also measured for the
purposes of this study.
Statistical Analysis
Analysis was performed using STATISTICA (Stat-
Soft, Tulsa, OK). Differences between time points
were analyzed using paired Student t test. Significance
is P < 0.05, and results are expressed as mean ± SEM.
Results
Patient Characteristics
Patients who had RYGB had greater BMls than
those who underwent AB (47.2 vs 44.2 kg/m^, re-
spectively) at baseline. At 6 months postsurgery, RYGB
subjects and AB subjects exhibited the same trend in
weight loss, but the patients undergoing RYGB had
more precipitous weight reduction in the same time
period than patients undergoing AB. By 6 months,
both patients undergoing RYGB and those undergoing
AB had similar BMls (34.6 vs 35.0 kg/m^) (Fig. I).
Diabetes Resolution
Thirty-one patients had RYGB and nine had AB. Of
these patients, 13 patients undergoing RYGB and one
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FIG. 1. Changes in body mass index (BMl) al 6 months after
Roux-en-Y gastric bypass (RYGB) and the adjustable gastric band
(AB). Weight changes are no different between the two surgical
groups, but significantly different at each time point lor the indi-
vidual surgery {P < 0.05).
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undergoing AB had impaired glucose tolerance or
frank diabetes as deñned by the American Diabetes
Association. By 6 months postsurgery, diabetes was
resolved in all but one patient who had undergone
RYGB and none of the patients who had undergone AB.
Insulin Sensitivity
In the nondiabetic subjects, peripheral insulin sen-
sitivity was similar in both RYGB and AB subjects, but
both were lower than normal-weight control subjects
(1.90 ± 0.3 and 1.36 ± 0.21 vs 2.50 Si units in normal-
weight control subjects, P < 0.05). Insulin sensitivity
was normalized in both nondiabetic RYGB and AB
groups at 6 months after surgery (3.02 ± 0.43 and 3.13 ±
0.85 Si units, respectively, P = not significant).
In RYGB subjects with prediabetes and diabetes,
insulin sensitivity was also lower than normal-weight
control subjects (2.04 ± 0.29 vs 2.50 Si units). Only
one patient undergoing AB had diabetes with very low
insulin sensitivity (0.11 Si units) at baseline. At 6
months, both surgical groups with diabetes had sig-
nificant improvements in insulin sensitivity (RYGB
2.04 ± 0.29 vs 3.38 ± 0.51, AB 0.11 to 5.46 Si units).
Insulirt Secretion
At baseline, nondiabetic RYGB subjects had much
greater insulin secretion compared with those who
were diabetic (672 ± 93 vs 30 ± 17 AIRg units, P <
0.005). Similarly, nondiabetic AB subjects had greater
insulin secretion compared with the one AB subject
who had diabetes (1011 ± 189 vs -33 AIRg units).
After surgery, nondiabetic patients undergoing
RYGB had a slight elevation in insulin secretion, but
then dropped below baseline 6 months postsurgery
(400 ± 42 AIRg units, P < 0.05 compared with base-
line). For both diabetic and nondiabetic patients
undergoing AB, insulin secretion exhibited minimal to
no change after surgery. In contrast, there was a pro-
nounced surge in insulin secretion in patients with
diabetes undergoing RYGB at 1 and 6 months (from
30 ± 25 at baseline to 110 ± 54 and 155 ± 38 AIR units
at 1 month and 6 months, respectively, P < 0.05).
ß-cell function measured by the DI was impaired at
baseline in subjects with prediabetes and diabetes com-
pared with those with normal glucose tolerance. Subjects
with diabetes who underwent RYGB experienced
immediate improvements in ß-cell function (from 61 ±
5 at baseline to 431 ± 45 and 703 ± 27 at 1 month and
6 months postsurgery, respectively, P < 0.05) (Table 1).
Discussion
It is widely accepted that T2DM is a combination of
dysfunctional insulin secretion by ß-cells and insulin
sensitivity (peripheral resistance) that results in im-
paired glucose homeostasis. Indeed, it is possible that
a patient with T2DM possesses very robust ß-cell
function to compensate for impaired peripheral resis-
tance or has combined attenuations in ß-cell function
and insulin sensitivity. Unfortunately, most patients
with T2DM presenting for weight loss surgery have no
information on the phenotype they possess.
In this study, we observed that patients with T2DM
undergoing RYGB exhibit and early restoration of
pancreatic ß-cell function measured by AIRg at 1 month.
There is a second phase of improved insulin-glucose
metabolism as exhibited by profound improvements in
peripheral Si at 6 months, which also led to an im-
proved DI. However, although the amount of weight
loss after AB was similar to RYGB, there is never an
improvement observed in AIRg in patients undergoing
AB, but only a modest improvement in insulin sensitivity
at 6 months, which is presumably from weight loss.
Data for normoglycemic patients undergoing both
weight loss procedures were also presented to give
context to the data observed in patients with diabetes.
Although it is beyond the scope of this discussion, it is
readily evident that morbidly obese patients without
diabetes probably maintain normoglycemia by high-
output insulin secretion, and once peripheral insulin
sensitivity improves after weight loss, insulin secretion
is reduced below baseline levels. Although there was
only one patient with diabetes who had AB, the data
found in normoglycemic patients undergoing AB
demonstrate that this procedure has virtually no effect
on ß-cell function. These data are also novel in that
there are no reports to our knowledge using IVGTT to
follow patients undergoing AB for weight loss.
It is not clear how the RYGB augments ß-cell func-
tion so soon after surgery, but several plausible
explanations have been proposed. Several exper-
imental studies have shown that ghrelin inhibits insulin
release in mice, rats, and humans.'° We and others
have shown early decreases in the "hunger" hormone
ghrelin after gastric bypass." Blockade of ghrelin
signaling markedly increase glucose-induced insulin
release in vitro. In high-fat diet-induced mildly obese
mice, ghrelin deficiency enhances insulin release and
prevents impaired glucose tolerance.'^ If these obser-
vations are validated, it is potentially feasible to manip-
ulate ghrelin signaling as a treatment for T2DM.
Another plausible and popular explanation is that the
intestinal rearrangement sending nutrients rapidly to
the distal small bowel induces a significant rise in
GLP-1.'^ Other investigators administering GLP-I
intravenously demonstrated a dose-dependent rise in
insulin secretion as well.''^ Insulin secretion by the ß-
cell undoubtedly occurs by multiple hormone stimuli
and the mechanisms are incompletely understood.
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TABLE I. Changes in Insulin Sensitivity (Si), ¡nsulin Secretion (A¡Rg), and ß-cell Function (D¡) at Baseline, I Month, and 6
Months after Weight Loss Surgery
Si units
AIRg unit.s
ß-cell function (Dl units)
Si units
AIRg units
ß-cell Function (Dl units)
Si units
AIRg units
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*Signiricantly different from nondiabetes, P < 0.05.
*Signincantly different from nondiabetes, P < 0.05.
There is also molecular explanation for the reversal
of peripheral insulin resistance after weight loss.'^
Bikman and colleagues demonstrated how muscles
become desensitized to insulin transport by inappro-
priate phosphorylation of the subcellular insulin-
receptor substrate-1 (by the inhibitor of kappa B kinase
ß, which commonly accumulates with high adipose
volumes.
In summary, this study showed that weight loss
between the patients undergoing AB and those
undergoing RYGB follow the same early trends, but
RYGB clearly induces an acute insulin response from
ß-cells early postoperatively, whereas AB does not.
With this information, it is possible that patients with
T2DM with intact or robust ß-cell function should be
offered a restrictive operation such as the sleeve gas-
trectomy or an adjustable gastric band as a way to
increase insulin sensitivity and thereby increase the DI.
In patients with attenuated ß-cell function, gastric
bypass may offer the more expeditious route to T2DM
reversal. In essence, the decision to choose a restrictive
procedure or a combined restrictive-malabsorptive pro-
cedure can potentially be made based on a patient's
insulin . secretion and peripheral resistance profile.
Although such a concept is ideal, there are other com-
plementary biomarkers that predict resolution of T2DM
such as inflammatory mediators"^ and adiponectin.'"'
Therefore, the ability to predict a patient's response from
weight loss surgery and choosing the ideal treatment
will most likely rely on an aggregate of related phys-
iological profiles rather than independent parameters.
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DISCUSSION
STEPHAN S. MCNATT, M.D. (Winston-Salem, NC;
Opening Discussion): In this study. Dr. Lin and his group
from Emory University shed more light on what has been a
mysteriously pleasant effect of bariatric surgery. Because
obesity and Type-2 diabetes are epidemic in our culture, this
research into how operations, as old as RYGB and as new as
laparoscopic adjustable gastric banding, real work is timely
and in some respects overdue. Dr. Lin and his group used a
simple test, the IVGTT, in an elegant manner to discern
changes in insulin resistance and ß-cell function in patients
undergoing RYGB and laparoscopic AB. Their work lends
more credence to the "foregut hypothesis," as promoted by
Rubino and others, as a mechanism for the acute resolution
of Type-2 diabetes in patients undergoing RYGB. In other
words, bypassing the duodenum and proximal jejunum
leads to improved ß-cell function and glucose homeostasis
by an as yet incompletely recognized mediator or pathway. In
addition, weight loss itself leads to decreased peripheral
insulin resistance and a consequent improvement in Type-2
diabetes through a different mechanism.
The lack of patients with diabetes in the laparoscopic
adjustable gastric band group is concerning. Why was there
only one patient ,in the band group with diabetes? Would
your study not have been strengthened by having more data
on patients with diabetes in this group? Would you agree
that it is difficult to make any meaningful observation about
the acute insulin response to glucose in patients with dia-
betes in the band group given that there was only one such
patient in the study? If, as you conclude, adjustable gastric
banding leads to improvements in insulin resistance only, it
would have been nice to see this in your data.
For both RYGB and AB, the resolution of diabetes occurs
at a rate of 80 per cent in the best of circumstances (ie, in
those who have had the disease for less than 5 years). Two
patients in your study, one in each group, did not see
resolution of their diabetes. Do you see the length of time
with Type-2 diabetes as being a potential confounding
variable for its resolution and was this accounted for in your
study? Are improvements in insulin resistance and ß-cell
function after RYGB or AB independent of the length of
time that a patient has had Type-2 diabetes?
Should we be testing all of our bariatric surgery candi-
dates with glucose tolerance tests and obtaining measures of
ß-cell function and peripheral insulin resistance?
Do you foresee a tailoring of bariatric procedures based on
a patient's comorbid conditions?
EUGENE SHIVELY, M.D. (Campbellsville, KY): Is
gastric bypass going to become a treatment for diabetes? If
so, what BMI are you going to choose and which patients
would we send to the bariatric surgeon?
LEENA KHAITAN, M.D. (Chardon, OH): Should we
test the insulin secretion in all of our patients? Sometimes they
will ask us whether they should have a band or bypass. Should
we test them preoperatively when we are discussing the pro-
cedures with the patients?
KIRBY BLAND, M.D. (Birmingham, AL): Could you
give us a little more insight into to what you suggest the
shutdown mechanism is physiologically from the proximal
or distal duodenum and jejunum? Is there a feedback loop as'
to why you shutdown insulin production? That seems like
the physiological consequences. People are doing the
banding because it is a much simpler operation and you do
not have to do a formal anastomosis.
PAUL WHITLOCK, M.D. (Statesboro, GA): My
understanding is that most people who have a band lose
approximately 100 pounds and then stabilize. What would
be the recurrence rate of diabetes after they stabilize?
EDWARD LIN, D.O. (Atlanta, GA; Closing Discussion):
We had only one patient undergo lap band surgery who had
diabetes, so there is some bias. The gastric bypass data have
been somewhat evolving over the last 5 years for this group.
When a patient with diabetes comes in and tells me that they
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want the AB procedure, 1 educate them. If they then want
the band, we will do it. It does not really dilute the data in
the patients undergoing gastric bypass versus the patients
undergoing banding. In the patients undergoing gastric
bypass, the insulin secretion definitely goes up when you do
the IVGTT at I month. Even with the patients with a normal
band, we do not see that.
The two patients who did not resolve their diabetes were
young patients younger than 40 years old, and we do not
know why.
We do not believe one operation fits all. We used to think
sleeve gastrectomy operations were a simple restrictive
operation, but we are fmding that these patients, when given a
meal challenge test, get dumping syndrome, and their dia-
betes goes away. We are finding different hormones change
with this operation. There is probably more than just one
operation for everyone. There are three efficacious oper-
ations out there. Safety is definitely an issue. The safest
operation is a restrictive operation. The Roux-en-Y bypass
would go to the back of the line.
Is diabetes treated by Roux-en-Y bypass? What BMI is
appropriate? The Centers for Medicare and Medicaid
Services disapproved that concept this year, because there
were not enough data. Data from Asia and Brazil on smaller
patients with a BMI of 30 kg/m^ and Type-2 diabetes
suggests improvement. If a patient has a BMI of 32 kg/m , is
diabetic, and can pay for the operation; 1 would not keep it
from them.
Should we test all of our patients? That would be ideal.
If we are serious about curing diabetes, we really need to
know the mechanism of the diabetes. Patients may be
low insulin secretors or have high peripheral insulin resist-
ance. There are patients who are both, and they do not do
well.
What is the mechanism of shutting down the insulin? That
is the million dollar question. There is a burnout factor.
There is a point where insulin production will be really high
to compensate for the peripheral resistance, but after awhile,
it burns out.
In our patients with diabetes who had the Roux-en-Y and
lost the excess weight, none had their diabetes recur. With
the patients undergoing banding, we have seen some have to
go back on oral medications. All you have to do is lose 40 to
45 pounds to gain the benefit of Type-2 diabetes resolution.
You have very little wiggle room when you do not lose that
much weight. If you lose 150 pounds with the Roux-en-Y
and you gain back 30 pounds, then you are still way ahead of
the game. My bias with the band is that if you only lose 60
pounds and you gain back 30, then that gives you a smaller
area to maintain that diabetes resolution.

